$CMPS News

Compass Pathways Elects Kathleen Tregoning to Board of Directors

Compass Pathways: A Trip Worth Taking Before The FDA Verdict

Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026

Compass Pathways Eyes Q4 FDA Filing for Psilocybin Depression Drug After Phase 3 Wins

This Psychedelics Stock Just Keeps Getting Hotter; Why Shares Bypassed A Profit-Taking Zone

Maxim Group Maintains Buy on Compass Pathways, Raises Price Target to $20

Assessing COMPASS Pathways (CMPS) Valuation After Strong Q1 2026 Earnings And Key FDA Milestones

Compass Pathways: Imminent Commercialization Should Provide Further Upside

Morgan Stanley Maintains Overweight on Compass Pathways, Raises Price Target to $17

RBC Capital Maintains Outperform on Compass Pathways, Raises Price Target to $22

Compass Pathways PLC (CMPS) Q1 2026 Earnings Call Highlights: Promising Advances in ...

Transcript: Compass Pathways Q1 2026 Earnings Conference Call

Transcript: Compass Pathways Q1 2026 Earnings Conference Call

Compass Pathways shares rise on Q1 results, accelerated FDA review

COMPASS Pathways plc (CMPS) Q1 2026 Earnings Call Transcript

BTIG Reiterates Buy on Compass Pathways, Maintains $14 Price Target

Compass Pathways Q1 Earnings Call Highlights

Compass Pathways Reports Strong Q1 Results, Shares Surge

Compass Pathways Q1 EPS $(0.30) Beats $(0.34) Estimate

Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026